相关实验视频

Updated: Jul 27, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

在HAWK和HARRIER的眼睛中治疗间隔延长的潜在可能性与nAMD疾病活动后负载阶段的HAWK和HARRIER

Ramin Tadayoni¹, Glenn J Jaffe², Frank G Holz³

¹Ophthalmology Department, Université Paris Cité, AP-HP, Lariboisière, Saint Louis and Fondation Adolphe de Rothschild Hospitals, 2 Rue Ambroise Paré, 75010, Paris, France. ramin.tadayoni@aphp.fr.

Ophthalmology and therapy

|June 9, 2023

概括

与aflibercept相比,brolucizumab在新血管与年龄相关的黄斑变性中显示出更好的疾病活动控制和液体分泌. 这表明,在第一年内,布罗卢齐祖马布的治疗间隔延长的可能性更高.

科学领域:

眼科医生眼科眼科
视网膜疾病视网膜疾病
药理疗法药理疗法药理疗法

背景情况:

在HAWK和HARRIER研究中,评估了brolucizumab与aflibercept对于新血管与年龄相关的黄斑变性 (nAMD).
由于研究设计,布罗卢齐祖马布的治疗方案最初以8周的间隔 (q8w) 固定,无论16周的疾病活性如何.
这项分析研究了布罗卢齐祖马布治疗眼睛的疾病活性和间隔延长潜力,最初需要 q8w 剂量.

研究的目的:

进行后期分析brolucizumab治疗眼睛的后续疾病活动.
评估在第一年治疗间隔延长的潜力,以持续疾病活动的眼睛.
为了比较brolucizumab与aflibercept在疾病控制和液体分辨率方面.

主要方法:

从HAWK和HARRIER研究中汇总的数据,重点是6毫克的布罗卢齐祖马布和阿弗利塞普特手臂.
疾病活动 (DA) 由蒙面调查人员使用光学连贯断层扫描 (OCT) 参数进行评估.
在16周,20周,32周,44周和48周评估了DA和液体存在.

主要成果:

与aflibercept (32.2%) 相比,在第16周治疗过brolucizumab的眼睛中,较少的眼睛 (22.8%) 显示出疾病活性.
与aflibercept相比,brolucizumab在随后的评估中 (第20周,第32周,第44周) 显示了较低的DA率,并减少了视内/视下液体.
视力敏度结果在16周的眼睛和DA之间是可比的.

结论:

在第16周,布罗卢齐祖马布治疗的眼睛具有持续的疾病活性,显示出比阿弗利塞普特治疗的眼睛更好的液体分辨率.
这些发现表明,在治疗的第一年内,brolucizumab在nAMD患者的治疗间隔延长的潜力更大.
布罗卢齐祖马布为管理nAMD提供了一个有前途的选择,有可能延长剂量间隔.

关键词:

抗VEGF疗法是一种治疗方法.布罗卢西祖马布 (brolucizumab) 是一种药物.疾病活动疾病活动时间间隔的延长神经血管与年龄相关的黄斑变性.

更多相关视频

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...